Status and phase
Conditions
Treatments
About
This study follows an open-label, single arm design with two periods with rosuvastatin, digoxin and ABBV-CLS-7262
Full description
Period 1: One single dose of rosuvastatin and one single dose of digoxin on Day 1.
Period 2: Multiple doses of ABBV-CLS-7262 once daily from Day 1 to Day 8. On Day 5, one single dose of rosuvastatin and one single dose of digoxin with the dose of ABBV-CLS-7262 on that day.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
12 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal